(MENAFN- GlobeNewsWire - Nasdaq) Opportunities include formulating investment strategies, identifying prime locations for cost-effective trials, leveraging data on trial success rates, and understanding enrollment trends globally. This aids in crafting competitive strategies and assessing clinical trial prospects across different regions and phases.

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "Reflux Esophagitis (Gastroesophageal Reflux Disease) - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets's offering.
This report provides an overview of Reflux Esophagitis (Gastroesophageal Reflux Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Reflux Esophagitis (Gastroesophageal Reflux Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Report Scope

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Reasons to Buy

• Assists in formulating key business strategies with regards to investment
• Helps in identifying prominent locations for conducting clinical trials which saves time and cost
• Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
• Supports understanding of trials count and enrollment trends by country in global therapeutics market
• Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
• Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

• Report Guidance
• The analyst Clinical Trials Report Coverage
• Clinical Trials by Region
• Clinical Trials and Average Enrollment by Country
• Top Five Countries Contributing to Clinical Trials in Asia-Pacific
• Top Five Countries Contributing to Clinical Trials in Europe
• Top Countries Contributing to Clinical Trials in North America
• Top Five Countries Contributing to Clinical Trials in Middle East and Africa
• Top Five Countries Contributing to Clinical Trials in Central and South America
• Clinical Trials by G7 Countries: Proportion of Reflux Esophagitis (Gastroesophageal Reflux Disease) to Gastrointestinal Clinical Trials
• Clinical Trials by Phase in G7 Countries
• Clinical Trials in G7 Countries by Trial Status
• Clinical Trials by E7 Countries: Proportion of Reflux Esophagitis (Gastroesophageal Reflux Disease) to Gastrointestinal Clinical Trials
• Clinical Trials by Phase in E7 Countries
• Clinical Trials in E7 Countries by Trial Status
• Clinical Trials by Phase
• In Progress Trials by Phase
• Clinical Trials by Trial Status
• Clinical Trials by End Point Status
• Subjects Recruited Over a Period of Time
• Clinical Trials by Sponsor Type
• Prominent Sponsors
• Top Companies Participating in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics Clinical Trials
• Prominent Drugs
• Latest Clinical Trials News on Reflux Esophagitis (Gastroesophageal Reflux Disease)
• Sep 23, 2025: Cinclus Pharma to Present Linaprazan Glurate Data at the European Gastroenterology Week (UEGW)
• Sep 12, 2025: Cinclus Announces Screening of First Patient in HEEALING 1 Phase III Trial Evaluating Linaprazan Glurate for the Treatment of Erosive GERD
• Aug 29, 2025: Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD)
• Aug 18, 2025: Onconic Therapeutics' P-CAB drug, Jacqbo, Has Successfully Completed Phase 3 Clinical Trials in China, and Has Applied for Product Approval
• Aug 15, 2025: Livzon: Voluntary Announcement Acceptance of Application for Registration and Marketing Authorization of JP-1366 Tablet
• Aug 07, 2025: Sebela Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
• Jul 30, 2025: Voluntary Announcement Completion of Patient Enrollment in Phase III Clinical Trial for Indication of Drug Anaprazole Sodium in Reflux Esophagitis
• Clinical Trial Profile Snapshots
• Appendix

Companies Featured

• Takeda Pharmaceutical Co Ltd
• AstraZeneca Plc
• Daewoong Co Ltd
• Eisai Co Ltd
• Johnson & Johnson
• Pfizer Inc
• Dr. Reddy's Laboratories Ltd
• Reckitt Benckiser Group Plc
• Krka dd Novo Mesto
• Thermo Fisher Scientific Inc

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN25112025004107003653ID1110396053